|[March 27, 2014]
VeriTeQ Rebrands its "Q Inside SmartMarker" to Lead its Radiation Dosimetry Business; Q Inside Smart Marker is World's First Implantable Sensor Cleared by FDA to Measure Radiation Dose Directly at the Tumor Site
DELRAY BEACH, Fla. --(Business Wire)--
VeriTeQ Corporation ("VeriTeQ" or "Company") (OTC Markets: VTEQ), a
provider of implantable medical device identification and radiation dose
measurement technologies, announced today that it is rebranding its Q
Inside SmartMarker to lead its radiation dosimetry business. Q Inside
SmartMarker (previously known as DVS SmartMarker®) is the only FDA-
cleared implantable radio frequency ("RF") radiation sensor that
provides localization of a tumor and measures radiation dose at the
tumor site. VeriTeQ's radiation dosimetry products have six FDA
clearances and CE approvals, and the Company has over 100 patents,
patents pending, and exclusive licenses.
Q Inside SmartMarker is an FDA-cleared, implantable radiation sensor for
use in breast and prostate cancer patients undergoing photon external
beam treatments. It is implanted in, or adjacent to, solid-mass tumors
and gathers data on the actual dose of radiation being delivered to the
tumor and surrounding normal tissue. Q Inside SmartMarker is intended to
be used in the balancing between delivering maximum dose to the tumor
while minimizing the impact to healthy tissue. The sensor can confirm
the treatment is conforming to the physician's plan, as even a small
deviation from planned dose can have a significant impact on patient
Scott R. Silverman, Chairman and CEO of VeriTeQ, stated, "Radiation
under-dosing and, perhaps more importantly, radiation overdosing have
been a top concernof the medical community for years. Confirming the
delivered dose of radiation is known to have a direct and significant
impact on treatment efficacy and patient survival rates, and our Q
Inside SmartMarker can support healthcare providers with this
potentially life-saving data."
According to the ECRI Institute, radiation or CT overdose make the list
of the Top 10 Technology Hazards each year going back at least eight
years. These hazards include radiation overdose and other errors during
radiation therapy; unnecessary exposures and radiation burns from
diagnostic radiology procedures; and exposure hazards from radiation
therapy and CT.
Q Inside SmartMarker is compatible with a large variety of commercially
available systems including, but not limited to, CyberKnife System,
Varian kV Trilogy System, TomoTherapy, Siemens (News - Alert) MV CBCT, and Resonant
VeriTeQ develops innovative, proprietary RFID technologies for
implantable medical device identification, and dosimeter technologies
for use in radiation therapy treatment. VeriTeQ offers the world's first
FDA cleared RFID microchip technology that can be used to identify
implantable medical devices, in vivo, on demand, at the point of care.
VeriTeQ's dosimeters provide patient safety mechanisms while measuring
and recording the dose of radiation delivered to a patient in real time.
For more information on VeriTeQ, please visit www.veriteqcorp.com.
Statements in this press release about our future expectations,
including that the Company's Q Inside SmartMarker will lead its
radiation dosimetry business, constitute "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933, Section
21E of the Securities Exchange Act of 1934, and as that term is defined
in the Private Litigation Reform Act of 1995. Such forward-looking
statements involve risks and uncertainties and are subject to change at
any time, and our actual results could differ materially from expected
results. These risks and uncertainties include, without limitation,
VeriTeQ's ability to raise capital; as well as other risks. Additional
information about these and other factors may be described in VeriTeQ's
Forms 10-Q, filed on August 9, 2013 and November 14, 2013, and future
filings with the Securities and Exchange Commission The Company
undertakes no obligation to update or release any revisions to these
forward-looking statements to reflect events or circumstances after the
date of this statement or to reflect the occurrence of unanticipated
events, except as required by law.
[ Back To TMCnet.com's Homepage ]